ABBV · NYSE · STOCK
AbbVie (ABBV) Stock Analysis
$264.99
52W $190.75 – $267.47
58/100
$468.22B
74.7
0.28
Is ABBV Bullish or Bearish?
Bullish.
Innellis AI committee rates AbbVie (ABBV) Buy with a composite score of 58/100
, based on 6 analysts with 67% agreement.
Last updated August 23, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +17.27 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -2.73 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 67.6% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 20.19) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 95.6% shows genuine earnings power backing the valuation — Value
- Dividend yield of 4.5% pays you to wait — Value
- EPS growing 67.6% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 70.2 is expensive by classic value standards — Value
- Price-to-book of 94.4x prices in significant intangible value — Value
- Debt-to-equity of 20.19 adds balance-sheet risk to the value case — Value
- High leverage (debt-to-equity 20.19) amplifies downside in a stress scenario — Risk
- Current ratio of 0.67 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 23, 2026
Overall Committee Score
58/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 52%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · High confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ ROE of 95.6% shows genuine earnings power backing the valuation
− P/E of 70.2 is expensive by classic value standards
Growth Analyst
bullish
78
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 67.6% YoY
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 20.19) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 57.7 to 57.7.
Comparing 2026-08-22 to 2026-08-23 (1 day apart).
Technical Analysis
RSI (14)
69.8
Neutral
MACD Histogram
1.330
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.89
Inside Bands
Price vs Moving Averages
EMA 9
$257.66
Above
EMA 21
$253.91
Above
EMA 50
$246.50
Above
EMA 200
$227.65
Above
Fundamental Analysis
Valuation
65
Growth
72
Profitability
45
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
74.7×
P/B Ratio
-79.08×
PEG Ratio
1.09
Dividend Yield
2.58%
52W High
$267.47
52W Low
$190.75
Quality & Growth
ROE
-12923.5%
ROA
315.5%
Gross Margin
7147.7%
Operating Margin
2932.2%
Revenue Growth YoY
—
Debt / Equity
-11.93
AI Fundamental Assessment
P/E ratio of 74.7 (rich relative to a 15-40x range); Price-to-book of -79.1x; PEG ratio of 1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -129.2%; Return on assets of 3.2%; Net margin of 9.8%; Gross margin of 71.5%; Current ratio of 0.81 (tight short-term liquidity); Debt-to-equity of -11.93; Free cash flow per share is positive (11.11); Most recent quarter missed estimates by 0.7%; EPS growth accelerating (-2.2% -> +37.7% QoQ); Average YoY EPS growth of 22.9%; Analyst estimates rising over recent quarters
Get the Full ABBV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →